{"filing":{"accession_number":"0000939767-26-000104","cik":"0000939767","ticker":"EXEL","company_name":"EXELIXIS, INC.","form":"8-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"exel-20260831.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/939767/000093976726000104/exel-20260831.htm"},"events":[{"id":30623,"run_id":28074,"accession_number":"0000939767-26-000104","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"The disclosure reports a favorable Federal Circuit Court of Appeals decision in Exelixis, Inc. v. MSN Laboratories Private Limited affirming that three Exelixis patents (11,091,439, 11,091,440, and 11,098,015) are not invalid, which establishes a January 15, 2030 earliest effective date for FDA approval of MSN's generic ANDA. This patent litigation outcome materially affects the timing and competitive landscape for a generic competitor's market entry and is therefore a material litigation event. The filing also references ongoing separate litigation involving U.S. Patent No. 12,128,039 with trial scheduled for November 2026, further underscoring the litigation context.","company_name":"EXELIXIS, INC.","ticker":"EXEL","filing_date":"2026-08-31","form":"8-K","submitted_at":null,"items":[{"id":33272,"accession_number":"0000939767-26-000104","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports a favorable Federal Circuit Court of Appeals decision in Exelixis, Inc. v. MSN Laboratories Private Limited affirming that three Exelixis patents (11,091,439, 11,091,440, and 11,098,015) are not invalid, which establishes a January 15, 2030 earliest effective date for FDA approval of MSN's generic ANDA. This patent litigation outcome materially affects the timing and competitive landscape for a generic competitor's market entry and is therefore a material litigation event. The filing also references ongoing separate litigation involving U.S. Patent No. 12,128,039 with trial scheduled for November 2026, further underscoring the litigation context.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T20:20:21.943977+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33272,"accession_number":"0000939767-26-000104","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports a favorable Federal Circuit Court of Appeals decision in Exelixis, Inc. v. MSN Laboratories Private Limited affirming that three Exelixis patents (11,091,439, 11,091,440, and 11,098,015) are not invalid, which establishes a January 15, 2030 earliest effective date for FDA approval of MSN's generic ANDA. This patent litigation outcome materially affects the timing and competitive landscape for a generic competitor's market entry and is therefore a material litigation event. The filing also references ongoing separate litigation involving U.S. Patent No. 12,128,039 with trial scheduled for November 2026, further underscoring the litigation context.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T20:20:21.943977+00:00","company_name":"EXELIXIS, INC.","ticker":"EXEL","filing_date":"2026-08-31"}]}